Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“MedCity news is a peerless national resource for those of us who really want to stay on top the very latest news in healthcare from incumbents to startups. ”

Elliot Menschik, DreamIt Ventures partner; Venturef0rth founder; Penn professor


Sign up for our daily newsletter


Gene therapy to restore muscle power to the heart nets UW spinoff $2.5 million

9:50 am by | 0 Comments

fake heart

Damaged or weakened heart muscle that can’t pump enough blood to the rest of the body causes a host of problems that fall under the classification of heart failure. Researchers at the University of Washington have discovered a gene-based method they think can restore strength to those muscles and are progressing toward the clinic

The startup they co-founded, BEAT BioTherapeutics Corp., just announced a $2.5 million seed round from CET Capital Partners and the W Fund, which invests in university spinouts in Washington. According to a U.S. Securities and Exchange Commission filing, that funding is coming in the form of debt.

BEAT says it will use the funds to move its therapy into clinical development. That therapy was built on researchers’ discovery that a small increase in a naturally occurring molecule called dATP appeared to boost the pumping power of the heart muscles, both in speed and force. In animal models, the treatment increases dATP levels in the heart and has shown to restore wall motion and improve overall cardiac performance, the company says.

Advertisement

That technology was spun into a company in 2008 with grants from the National Institutes of Health. Seattle-based BEAT is now led by Michael Kranda, a former chief operating officer of Immunex and CEO of Vaccinogen.

Celladon Corp. and Belgium-based Cardio3 Biosciences are among the companies with heart failure gene therapies already in clinical trials.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Deanna Pogorelc

By Deanna Pogorelc MedCity News

Deanna Pogorelc is a Cleveland-based reporter who writes obsessively about life science startups across the country, looking to technology transfer offices, startup incubators and investment funds to see what’s next in healthcare. She has a bachelor’s degree in journalism from Ball State University and previously covered business and education for a northeast Indiana newspaper.
More posts by Author

0 comments